Cover Image
市場調查報告書

醫藥品、生物科技、診斷相關經營者的共同R&D的條件及契約

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2016

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 308759
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品、生物科技、診斷相關經營者的共同R&D的條件及契約 Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2016
出版日期: 2016年09月01日 內容資訊: 英文
簡介

本報告提供全球主要生命科學經營者的共同研究開發的條件及契約的相關調查,共同R&D契約的特徵,優點,近幾年的趨勢,共同R&D契約結構,主要經營者間契約的案例研究,大型經營者的契約詳細內容,調查期間中簽下合約一覽等的詳細內容彙整。

摘要整理

第1章 簡介

第2章 共同R&D契約的趨勢

  • 簡介
  • 共同R&D契約定義
  • 共同R&D契約導向成功的要素
  • 共同R&D發揮有效性的場面
  • 共同R&D契約的特性
  • 近幾年的共同R&D契約的趨勢
  • 今後的共同R&D契約

第3章 共同R&D契約結構:概要

  • 簡介
  • 單因素 vs 多因素的共同R&D契約
  • 單因素的共同R&D契約結構
    • 共同R&D契約範例
      • 案例研究1:Marinus Pharmaceuticals、NovaMedica
      • 案例研究2:Idenix Pharmaceuticals、Janssen Pharmaceuticals
  • 廣泛的合夥協議一部分的共同R&D
    • 共同R&D契約和許可證條款範例
      • 案例研究3:4D Molecular Therapeutics、UniQure
      • 案例研究4:Kyowa Hakko Kirin、Ultragenyx Pharmaceuticals
    • 共同R&D契約的選擇權條款範例
      • 案例研究5:Forest Laboratories、Trevena
      • 案例研究6:Abbvie、Receptos

第4章 主要共同R&D契約

  • 簡介
  • 各契約額的主要共同R&D契約
  • 最活躍的共同R&D契約締結經營者
  • 以大型製藥公司的共同R&D契約為中心的動向
  • 以大生物科技企業的共同R&D契約為中心的動向

第5章 共同R&D契約條件的基準

  • 簡介
  • 共同R&D契約主要的金額
    • 預付款金
    • 目標成就報酬
    • 權利金費率

第6章 大型製藥公司的共同R&D契約

  • 簡介
  • 共同R&D契約的利用方法
  • 簽訂了共同R&D契約的企業一覽

第7章 大生物科技企業的共同R&D契約

  • 簡介
  • 共同R&D契約的利用方法
  • 簽訂了共同R&D契約的企業一覽

第8章 共同R&D契約的要覽

  • 簡介
  • 企業清單A-Z
  • 各治療領域
  • 各開發階段
  • 各技術區域

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2064

The ‘Global Collaborative R&D Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2016’ report provides comprehensive understanding and unprecedented access to the collaborative R&D partnering deals and agreements entered into by the worlds leading healthcare companies

The ‘Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016’ report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.

This report provides details of the latest collaborative R&D deals announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date with the latest information, the report provides details of collaborative R&D deals from 2010 to 2016.

There has been a long standing willingness for parties to enter collaborative R&D deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages.

Collaborative R&D is a specific type of partnering deal whereby the parties to the deal agree to collaborate on the research and development and subsequently commercialize a compound, product or technology.

There are several forms of a collaborative R&D deal; A traditional collaborative R&D arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for agreed payments and royalties on subscequent sales of product(s) derived from the intellectual property.

In more recent times, licensing is often the outcome of a successful period of collaborative R&D on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the collaborative R&D agreement governs who has permission to commercialize and what payments are due should commercialization proceed.

The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to comoercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all collaborative R&D deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in collaborative R&D as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of collaborative R&D deals. The chapter includes numerous case studies to enable understanding of both pure collaborative R&D deals and multicomponent deals where collaborative R&D forms a part.

Chapter 4 provides a review of the leading collaborative R&D deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a review of the top 50 most active biopharma companies in collaborative R&D. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 6 provides a comprehensive review of collaborative R&D financials for deals announced since 2010, including headline value, upfront, milestone payments and royalty rates, providing both benchmark data and access to individual deal financials.

Chapter 7 provides a comprehensive and detailed review of collaborative R&D deals signed and announced since 2010 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends and activities in collaborative R&D dealmaking since 2010.

In addition, a comprehensive appendix is provided organized by company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about collaborative R&D partnering in the research, development and commercialization of technologies and products.

Key benefits

‘Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016’ provides the reader with the following key benefits:

  • In-depth understanding of collaborative R&D deal trends since 2010
  • Analysis of the structure of collaborative R&D agreements with numerous real life case studies
  • Comprehensive listing of over 4,500 collaborative R&D deals since 2010, together with deal terms, value and press release
  • Comprehensive access to actual collaborative R&D contracts entered into by the world's life science companies
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Insight into the terms included in a collaborative R&D agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016’ is intended to provide the reader with an in-depth understanding of the collaborative R&D trends and structure of deals entered into by leading life science companies worldwide.

‘Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016’ includes:

  • Trends in collaborative R&D dealmaking in the biopharma industry since 2010
  • Analysis of collaborative R&D deal structure
  • Case studies of real-life collaborative R&D deals
  • Comprehensive listing of over 4,500 collaborative R&D deals since 2010
  • Access to collaborative R&D contract documents
  • Key financial benchmarks for headline, upfront, milestone and royalty rates
  • The leading collaborative R&D deals by value since 2010
  • Most active collaborative R&D dealmakers since 2010
  • The leading collaborative R&D partnering resources

In ‘Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016’ available deals and contracts are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The ‘Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016’ report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How do milestone align with clinical stage development phases?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Collaborative R&D Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2016’ report provides the reader with the following key benefits:

  • In-depth understanding of collaborative R&D deal trends since 2010
  • Analysis of the structure of collaborative R&D agreements with numerous real life case studies
  • Comprehensive listing of all collaborative R&D deals since 2010, together with deal terms, value and press release
  • Comprehensive access to actual collaborative R&D contracts entered into by the world's life science companies
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Insight into the terms included in a collaborative R&D agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in collaborative R&D dealmaking

  • 2.1. Introduction
  • 2.2. Definition of collaborative R&D partnering
  • 2.3. Success factors for collaborative R&D deals
  • 2.4. When collaborative R&D can be useful
  • 2.5. Attributes of collaborative R&D deals
  • 2.6. Trends in collaborative R&D deals since 2010
    • 2.6.1. Collaborative R&D dealmaking by year, 2010 to 2016
    • 2.6.2. Collaborative R&D dealmaking by phase of development, 2010 to 2016
    • 2.6.3. Collaborative R&D dealmaking by industry sector, 2010 to 2016
    • 2.6.4. Collaborative R&D dealmaking by therapy area, 2010 to 2016
    • 2.6.5. Collaborative R&D dealmaking by technology type, 2010 to 2016
    • 2.6.6. Collaborative R&D dealmaking by most active company, 2010 to 2016
  • 2.7. The future of collaborative R&D deals

Chapter 3 - Overview of collaborative R&D deal structure

  • 3.1. Introduction
  • 3.2. Pure versus multi-component collaborative R&D deals
  • 3.3. Pure collaborative R&D agreement structure
    • 3.3.1. Example collaborative R&D agreements
    • 3.3.1.a. Case study 1: Marinus Pharmaceuticals - NovaMedica
    • 3.3.1.b. Case study 2: Idenix Pharmaceuticals - Janssen Pharmaceuticals
  • 3.4. Collaborative R&D as part of a wider alliance agreement
    • 3.4.1. Example collaborative R&D agreements and their licensing clauses
    • 3.4.1.a. Case study 3: 4D Molecular Therapeutics - UniQure
    • 3.4.1.b. Case study 4: Kyowa Hakko Kirin - Ultragenyx Pharmaceuticals
    • 3.4.2. Example licensing option right clauses in collaborative R&D deals
    • 3.4.2.a. Case study 5: Forest Laboratories - Trevena
    • 3.4.2.b. Case study 6: Abbvie - Receptos

Chapter 4 - Leading collaborative R&D deals

  • 4.1. Introduction
  • 4.2. Top collaborative R&D deals by value

Chapter 5 - Top 50 most active collaborative R&D dealmakers

  • 5.1. Introduction
  • 5.2. Top 50 most active collaborative R&D dealmakers

Chapter 6 - Collaborative R&D deal term financials

  • 6.1. Introduction
  • 6.2. Collaborative R&D partnering headline values
  • 6.3. Collaborative R&D deal upfront payments
  • 6.4. Collaborative R&D deal milestone payments
  • 6.5. Collaborative R&D royalty rates

Chapter 7 - Collaborative R&D contract directory 2010 - 2016

  • 7.1. Introduction
  • 7.2. Collaborative R&D deals with contracts 2010 to 2016

Appendices

  • Appendix 1 - Collaborative R&D dealmaking by companies A-Z
  • Appendix 2 - Collaborative R&D dealmaking by industry sector
  • Appendix 3 - Collaborative R&D dealmaking by stage of development
  • Appendix 4 - Collaborative R&D dealmaking by therapy area
  • Appendix 5 - Collaborative R&D dealmaking by technology type

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

TABLE OF FIGURES

  • Figure 1: Definition of collaborative R&D
  • Figure 2: Situations where collaborative R&D can prove useful
  • Figure 3: Key attributes of a collaborative R&D deal
  • Figure 4: Trends in Collaborative R&D deal announcements, 2010 to 2016
  • Figure 5: Collaborative R&D deals signed at each phase of development, 2010 to 2016
  • Figure 6: Collaborative R&D deals by industry sector, 2010 to 2016
  • Figure 7: Collaborative R&D deals by therapy area, 2010 to 2016
  • Figure 8: Collaborative R&D deals by technology type, 2010 to 2016
  • Figure 9: Top 50 most active collaborative R&D dealmakers, 2010 to 2016
  • Figure 10: Collaborative R&D agreements - what should a contract include?
  • Figure 11: Components of the collaborative R&D deal structure
  • Figure 12: Top collaborative deals by value 2010 to 2016
  • Figure 13: Most active collaborative R&D dealmakers 2010 to 2016
  • Figure 14: Collaborative R&D deals with a headline value
  • Figure 15: Collaborative R&D deals with an upfront value
  • Figure 16: Collaborative R&D deals with a milestone value
  • Figure 17: Collaborative R&D deals with a royalty rate value
Back to Top